Lyon Street Capital LLC increased its stake in IRIDEX Corporation (NASDAQ:IRIX) by 4.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 442,647 shares of the medical equipment provider’s stock after purchasing an additional 19,059 shares during the period. IRIDEX accounts for about 1.6% of Lyon Street Capital LLC’s portfolio, making the stock its 26th largest position. Lyon Street Capital LLC owned about 3.82% of IRIDEX worth $4,148,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in IRIX. Susquehanna International Group LLP acquired a new stake in IRIDEX in the 2nd quarter worth approximately $196,000. Ingalls & Snyder LLC acquired a new stake in IRIDEX in the 3rd quarter worth approximately $234,000. LMR Partners LLP acquired a new stake in IRIDEX in the 2nd quarter worth approximately $242,000. Goldman Sachs Group Inc. acquired a new stake in IRIDEX in the 2nd quarter worth approximately $607,000. Finally, Osborne Partners Capital Management LLC acquired a new stake in IRIDEX in the 3rd quarter worth approximately $673,000. Institutional investors own 49.31% of the company’s stock.
Shares of IRIDEX Corporation (NASDAQ:IRIX) opened at $8.14 on Wednesday. IRIDEX Corporation has a 12 month low of $7.43 and a 12 month high of $16.37.
A number of research firms recently commented on IRIX. Zacks Investment Research upgraded shares of IRIDEX from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Roth Capital reiterated a “buy” rating and issued a $13.00 target price on shares of IRIDEX in a research note on Friday, November 3rd.
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD).
Receive News & Ratings for IRIDEX Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX Corporation and related companies with MarketBeat.com's FREE daily email newsletter.